Pioglitazone associated with lower blood leptin in diabetes

Pioglitazone associated with lower blood leptin in diabetes
(HealthDay)—Compared to placebo, pioglitazone is associated with significantly lower blood leptin levels in patients with type 2 diabetes, according to a meta-analysis published online Dec. 1 in the Journal of Diabetes Investigation.

Satoshi Ida, from Ise Red Cross Hospital in Japan, and colleagues conducted a meta-analysis of (RCTs) investigating the effects of pioglitazone on blood levels in patients with type 2 diabetes. Ten RCTs met eligibility criteria and were included.

The researchers found that the pioglitazone group had significantly lower blood leptin levels compared to the placebo group (standardized mean difference, −0.58; 95 percent confidence interval, −1.12 to −0.05 percent; P = 0.02). There were no significant leptin differences between the and oral antidiabetic drug groups (standardized mean difference, −0.01; 95 percent confidence interval, −0.2 to 0.19 percent; P = 0.93). The authors noted that relatively few RCTs were included in the study and that there was a high level of statistical heterogeneity, which could have affected the results.

"The present study had many limitations, warranting caution for the interpretation of its results and the extrapolation of the findings to other populations," the authors write. "Considering the limitations, we believe that further studies are necessary."


Explore further

Greater benefit for pioglitazone in high-risk patients post stroke

More information: Abstract
Full Text

Copyright © 2017 HealthDay. All rights reserved.

Citation: Pioglitazone associated with lower blood leptin in diabetes (2017, December 21) retrieved 23 January 2019 from https://medicalxpress.com/news/2017-12-pioglitazone-blood-leptin-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more